- Drug Pipelines
- December 2019
- 56 Pages
Global
From €3363EUR$3,500USD£2,887GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- July 2021
- 84 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Report
- July 2022
- 277 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- October 2022
- 292 Pages
Global
From €5506EUR$5,730USD£4,726GBP
- Report
- July 2022
- 315 Pages
Global
From €5592EUR$5,820USD£4,801GBP
- Report
- May 2023
- 160 Pages
Global
From €5764EUR$5,999USD£4,948GBP
The Sickle Cell Drug market is a subset of the larger Hematological Drugs market. It is composed of drugs used to treat sickle cell disease, a genetic disorder that affects red blood cells. These drugs are used to reduce the frequency of painful episodes, reduce the risk of organ damage, and improve the quality of life for those affected. Common treatments include hydroxyurea, which helps to reduce the number of sickle cells in the blood, and L-glutamine, which helps to reduce the risk of organ damage. Other treatments include blood transfusions, stem cell transplants, and gene therapy.
Companies in the Sickle Cell Drug market include Novartis, GlaxoSmithKline, Pfizer, Sanofi, and Merck. Show Less Read more
